If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna shares surge 16% to $50 on five-year melanoma vaccine data showing 49% risk reduction. Analysts target $29.93 despite ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by 49%.

Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

The vaccine maker is expanding beyond its COVID-focused offerings.

In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

We recently published 10 Stocks Jim Cramer Talked About. Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer talked ...